KCT0000907已完成未知
A randomized, open-label, single dose, 3-sequence and 3-period partial replicated crossover clinical study to compare pharmacokinectic characteristics of Eperisone Hydrochloride and Aceclofenac with HCP1104 treatment to those of co-administration of Eperisone Hydrochloride 50mg tablet and Aceclofenac 100mg tablet in healthy adult male volunteers
Hanmi Pharm0 个研究点目标入组 30 人开始时间: 待定最近更新:
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional Study
入排标准
- 年龄范围
- 20(Year) 至 45(Year)（—）
- 性别
- Male
入选标准
- •1) Healthy male volunteers, age between 20 and 45
- •2) BMI of >20kg/m2 and <28kg/m2 subject
- •3) Informed of the investigational nature of this study and voluntarily agree to participate in this study
排除标准
- •1) Use of any prescription medication within 14 days prior to Day 1
- •2) Use of any medication within 7 days prior to Day 1
- •3) Participation in another clinical study within 60 days prior to start of study drug administration
研究者
相似试验
已完成
不适用
Comparative pharmacokinetics between fixed-dose combination of pitavastatin/valsartan 4/160 mg and the corresponding loose combination through partial replicated crossover desigKCT0005957JW Pharmaceutical Corporation54
Unknown
不适用
Comparative bioavailability study between Remdesivir oral solution and Remdesivir for injection in healthy adultCTRI/2021/08/035346Cipla Ltd India16
已完成
不适用
A study to compare the pharmacokinetics and safety/tolerability of BS-105 enteric-coated tablet A” or BS-105 enteric-coated tablet B” of Bio-Synectics to original drug in healthy male subjects (Pilot study)Certain infectious and parasitic diseasesKCT0004007Bio-Synectics9
已完成
不适用
Relative bioavailability study of two candidate tablet formulations of 16mg candesartan cilexetil (GW615775) compared with the reference product Atacand (16mg candesartan cilexetil, AstraZeneca) in healthy human subjects under fasting conditionsCTRI/2014/12/005269GlaxoSmithKline Research and Development Limited18
招募中
不适用
Relative bioavailability of montelukast sodium 5mg from two candidate chewable tablet formulations of GW483100 relative to one 5mg chewable tablet of reference montelukast sodium in healthy adult subjects under fasting conditionsCTRI/2015/03/005625GlaxoSmithKline Research and Development Limited18